Status of Pharmaceutical Production In Japan

17 March 1997

For 1995, the latest figures available, Japan's total pharmaceuticalproduction amounted to 6,168.1 billion yen ($50.71 billion), an increase of 7.3% on the previous year, according to the Japan Pharmaceutical Manufacturers Association's Data Book.

Although growth of pharmaceutical production was dull in the 1990s, even minus 2.2% was recorded for 1994, the JPMA says that after an interval of six years a high growth of 5% or more was achieved in 1995. Over the past five years, however, the average annual growth has remained at around 2%.

Therapeutic Component Ratio With the aging population, weights on the drugs for cardiovascular, central nervous, digestive system, diabetes mellitus, etc have been increasingly enlarged, notes the JPMA. Production of cardiovasculars for 1995 for the first time exceeded the 1,000 billion yen level, and accounted for 19.1% of total drug production.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight